Clinical trial NCT01716975: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Schizophrenia
Impaired Cognition
Keywords: Schizophrenia
Cognition
Cognition Impairment
Alpha-7 nAChR
Lead sponsor: FORUM Pharmaceuticals Inc
Sponsor class: INDUSTRY
Collaborators: name: Syneos Health
name: NeuroCog Trials, Inc.
First posted: 2012-10-30
Enrollment: 767
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.


Eligibility criteria: Inclusion Criteria:

* Age 18 to 50 years of age, inclusive
* Signed informed consent, indicating that the subject understands the purpose of and procedures required for the study, before the initiation of any study specific procedures. Subjects who are unable to provide informed consent will not be included in the study.
* Resides in a stable living situation, according to the investigator's judgment, and must have an identified informant who should be consistent throughout the study. If possible, the informant should accompany the subject or be available for in person ratings at the screening, baseline (Day 1), and final study visits. In person informant ratings on all relevant study visits are preferred whenever possible. However, if the informant is not available for in person ratings, telephone interview is acceptable. The informant must be available for a telephone interview throughout the study at all visits. As long as both the informant visit and subject visit are within the study visit windows, it is not necessary that they occur on the same day. The informant must interact with the subject at least 2 times a week.
* Diagnosis of Schizophrenia of at least 3 years duration. This diagnosis can be established utilizing the SCID-I, direct clinical assessments, family, informants, and confirmation of diagnosis from clinical sources. These may include medical records, confirmation of diagnosis by treating clinician through telephone contact, or written confirmation from treating clinic. If the listed sources are not available, other sources of diagnostic confirmation may also be acceptable after discussion with the medical monitor.
* Treated with atypical antipsychotic drug (in any approved dosage form) other than Clozapine at a stable dose for at least 8 weeks prior to screening and be clinically stable; the subject must remain clinically stable (in the opinion of the principal investigator) through randomization. The use of up to 2 atypical antipsychotic drugs is permitted, as long as in the opinion of the investigator, the second medication is not required to control treatment-resistant or intractable psychotic symptoms. No subject will be washed off antipsychotic therapy to become eligible for this study.
* Schizophrenia clinical symptom burden severity defined by the following: a Brief Psychiatric Rating Scale (BPRS) Conceptual Disorganization item score ≤ 4; and a BPRS Hallucinatory Behavior item score ≤ 5, or an Unusual Thought Content item score ≤ 5. Either Hallucinatory Behavior or Unusual Thought Content, but not both, may have a score of 6 (but not \> 6).
* Simpson-Angus Scale (SAS) total score ≤ 6
* Calgary Depression Scale for Schizophrenia (CDSS) total score ≤ 10
* General health status acceptable for participation in a 26-week clinical study
* Fertile, sexually active subjects (men and women) must use an effective method of contraception during the study
* Fluency (oral and written) in the language in which the standardized tests will be administered
* The ability to refrain from using any tobacco or other nicotine-containing products for at least 30 minutes before any cognitive testing

Exclusion Criteria:

* Hospitalization within 12 weeks before screening or during the screening period, or change of antipsychotic medication or dose within 8 weeks before screening or during the screening period.
* Participation in another therapeutic (medication administration) clinical study within the past 2 months.
* Psychiatric hospitalization or incarcerations due to breakthrough symptoms or acute exacerbations for a period of 3 months before screening. Subjects with a recent "social" hospitalization or incarceration may be entered into screening after consultation with the medical monitor
* Likelihood, in the opinion of the investigator, that either the subject or informant will be unable to complete a 26-week study
* Treatment with prohibited antipsychotic drug, and/or treatment with more than 2 permitted antipsychotic drugs. Treatment with a first-generation antipsychotic drug (typical antipsychotic) is prohibited unless it is administered at a low dose after discussion with the medical monitor
* Current treatment with any anticholinergic agent
* Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria met for alcohol abuse within the past 3 months or substance abuse (other than nicotine) within the last 6 months before screening
* Significant suicide risk as defined by 1) suicidal ideation as endorsed on items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within the past year; 2) suicidal behavior detected by the C-SSRS during the past 2 years, or 3) psychiatric interview and examination
* Stroke within 6 months before screening, history of brain tumor, subdural hematoma, or other clinically significant neurological condition, head trauma with loss of consciousness within 12 months before screening
* Monoamine oxidase inhibitor antidepressants or tricyclic medications used in antidepressant doses are excluded. Other antidepressant medications are allowed if the subject has been treated with a stable dose for at least 3 months before screening
* Immunosuppressants, mood stabilizers, chronic use of a sedative hypnotic drug, chronic intake of clinically significant doses of opioid containing analgesics or any current methadone treatment all in the judgment of the investigator may be permitted depending on the circumstance
* Use of Central Nervous System(CNS) stimulants
* Nicotine therapy (including patches), varenicline (Chantix), or similar therapeutic agent within the last six months before screening
* Use of a benzodiazepine medication is allowed if the subject has not had a change in medication or dose for at least 3 months. For subjects prescribed benzodiazepines, short-acting benzodiazepines are to be used whenever possible. Use of longer-acting benzodiazepines may be acceptable if prior authorization is obtained from the medical monitor. When possible, benzodiazepines should not be administered within 3 hours before cognitive testing. The use of more than one sedative-hypnotic medication is not allowed.

Primary outcomes:
measure: Change from Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) to Day 182
timeFrame: Baseline to Day 182 or Early Termination
measure: Change from Baseline in the Schizophrenia Cognition Rating Scale (SCoRs) to Day 182
timeFrame: Baseline to Day 182 or Early Termination
measure: Safety and Tolerability of EVP-6124 or Placebo in Subjects with Schizophrenia
timeFrame: Screening (Day -42 to Day -15) to Day 182 or Early Terminiation
Secondary outcomes:
measure: Change from Baseline in the Positive and Negative Symptom Scale (PANSS) to Day 182
timeFrame: Baseline to Day 182 or Early Termination
measure: Change from Baseline in the Clinical Global Impression-Severity (CGI-S) to Day 182
timeFrame: Baseline to Day 182 or Early Termination
measure: Change from Baseline in the Clinical Global Impression Change Scale (CGI-C) to Day 182
timeFrame: Baseline to Day 182 or Early Termination
measure: Change from Baseline in the EuroQOL-5D (EQ-5D) to Day 182
timeFrame: Baseline to Day 182 or Early Termination
Other outcomes:
Locations:
city: Phoenixville
country: United States
state: Arizona
city: Little Rock
country: United States
state: Arkansas
city: Cerritos
country: United States
state: California
city: Chino
country: United States
state: California
city: Costa Mesa
country: United States
state: California
city: Garden Grove
country: United States
state: California
city: Glendale
country: United States
state: California
city: Norwalk
country: United States
state: California
city: Oakland Park
country: United States
state: California
city: Oakland
country: United States
state: California
city: Oceanside
country: United States
state: California
city: Riverside
country: United States
state: California
city: San Diego
country: United States
state: California
city: San Gabriel
country: United States
state: California
city: Santa Ana
country: United States
state: California
city: Sherman Oaks
country: United States
state: California
city: Washington
country: United States
state: District of Columbia
city: Bradenton
country: United States
state: Florida
city: Miami Springs
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: North Miami
country: United States
state: Florida
city: Orlando
country: United States
state: Florida
city: Marietta
country: United States
state: Georgia
city: Smyrna
country: United States
state: Georgia
city: Chicago
country: United States
state: Illinois
city: Oak Brook
country: United States
state: Illinois
city: Oak Park
country: United States
state: Illinois
city: Wichita
country: United States
state: Kansas
city: Lake Charles
country: United States
state: Louisiana
city: Shreveport
country: United States
state: Louisiana
city: Rockville
country: United States
state: Maryland
city: Boston
country: United States
state: Massachusetts
city: St. Charles
country: United States
state: Missouri
city: St. Louis
country: United States
state: Missouri
city: Lincoln
country: United States
state: Nebraska
city: Princeton
country: United States
state: New Jersey
city: Jamaica
country: United States
state: New York
city: New York
country: United States
state: New York
city: Rochester
country: United States
state: New York
city: Charlotte
country: United States
state: North Carolina
city: Beachwood
country: United States
state: Ohio
city: Oklahoma City
country: United States
state: Oklahoma
city: Jenkintown
country: United States
state: Pennsylvania
city: Austin
country: United States
state: Texas
city: Dallas
country: United States
state: Texas
city: Salt Lake City
country: United States
state: Utah
city: Bellevue
country: United States
state: Washington
city: Richland
country: United States
state: Washington
city: Spokane
country: United States
state: Washington
city: Banfield
country: Argentina
state: Buenos Aires
city: Rosario
country: Argentina
state: Santa Fe
city: Caba
country: Argentina
city: Mendoza
country: Argentina
city: Santiago del Estero
country: Argentina
city: Adelaide
country: Australia
state: South Australia
city: Mt. Claremont
country: Australia
state: Western Australia
city: Salvader
country: Brazil
state: BA
city: Belo Horizonte
country: Brazil
state: MG
city: Curitiba
country: Brazil
state: Parana
city: Medellin
country: Colombia
state: Antioquia
city: Barranquilla
country: Colombia
state: Atlantico
city: Pereira
country: Colombia
state: Risaralda
city: Bogota D.C.
country: Colombia
city: Firenze
country: Italy
state: FL
city: Milan
country: Italy
state: MI
city: Ban
country: Italy
city: Barl
country: Italy
city: Catania
country: Italy
city: Lucca
country: Italy
city: Milano
country: Italy
city: Pisa
country: Italy
city: Roma
country: Italy
city: Monterrey
country: Mexico
state: Nuevo Leon
city: Mexico, D.F
country: Mexico
city: San Luis Potosi
country: Mexico
city: Belchatow
country: Poland
city: Chelmno
country: Poland
city: Karakow
country: Poland
city: Kielce
country: Poland
city: Kotarbinskiego
country: Poland
city: Sosnowiec
country: Poland
city: Torun
country: Poland
city: Wroclaw
country: Poland
city: Campulung
country: Romania
state: Arges
city: Oradea
country: Romania
state: Bihor
city: Cluj-Napoca
country: Romania
state: Cluj
city: Palazu-Mare
country: Romania
state: Constanta
city: Targu-Mures
country: Romania
state: Munes
city: Bucuresti
country: Romania
state: Sector 4
city: Iasi
country: Romania
city: Saint-Petersburg
country: Russian Federation
state: Leningrad
city: Smolensk
country: Russian Federation
state: Smolensk region
city: Moscow
country: Russian Federation
city: Saint-Petersburg
country: Russian Federation
city: Samara
country: Russian Federation
city: Yaroslavl
country: Russian Federation
city: vil. Stepanivka
country: Ukraine
state: Kherson
city: Dnipropetrovsk
country: Ukraine
city: Kharkiv
country: Ukraine
city: Kyiv
country: Ukraine
city: Lviv
country: Ukraine
city: Poltava
country: Ukraine
city: Vinnytsia
country: Ukraine
city: Cambridge
country: United Kingdom
state: Cambridgeshire
city: Newcastle-upon-Tyne
country: United Kingdom
state: Tyne and Wear
city: Exeter
country: United Kingdom
city: London
country: United Kingdom
Study officials:
References: